Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by
circulating autoantibodies that recognize cell surface phospholipids and phospholipid …

Objective To develop new antiphospholipid syndrome (APS) classification criteria with high
specificity for use in observational studies and trials, jointly supported by the American …

Although the knowledge of APS pathogenesis has grown in recent years, the management
principles and strategies are largely unchanged. There is an unmet need for evaluating …

Background Thrombosis is a unique complication of coronavirus disease 2019 (COVID-19).
Although antiphospholipid antibodies (aPL) are detected in COVID-19 patients, their clinical …

Antiphospholipid syndrome (APS) has been characterized by a variety of vascular and
pregnancy manifestations related to an interplay between thrombotic and inflammatory …

Several antiphospholipid antibody (aPL) profiles (“triple” and lupus anticoagulant [LA]
positivity) are associated with a higher risk for clinical manifestations of antiphospholipid …

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by
thrombotic and non-thrombotic macro-and microvascular manifestations and pregnancy …

Objectives Our primary objective was to quantify damage burden measured by Damage
Index for Antiphospholipid Syndrome (DIAPS) in aPL-positive patients with or without a …

Obiectives This study aims to prospectively evaluate the frequency and adverse
consequences of diagnostic delay and misdiagnosis in a cohort of patients with thrombotic …

The appropriate secondary thromboprophylactic strategies for Antiphospholipid syndrome
(APS) with arterial thrombosis remain controversial. This study aimed to assess the relative …